COLL

Over the past six months, Collegium Pharmaceutical's stock price experienced significant fluctuations, losing 40.28% from $36.72 to $21.93 over 61 trading days, with a range from $21.43 to $37.70. A notable event was an 18.55% decline on August 6, 2026, following Q2 2026 financial results, despite beating adjusted EPS expectations. Other events include a $50 million accelerated share repurchase program on August 13, 2026, leading to a +9.53% increase; participation in investor conferences announced on September 8, 2026; the launch of 'Start Talking ADHD' on October 6, 2026; and a downgrade to 'strong sell' by Zacks Research on October 8, 2026. Overall, the stock declined 33.5% between October 9, 2025, and October 9, 2026.